

**IN THE UNITED STATES DISTRICT COURT FOR THE
DISTRICT OF UTAH, CENTRAL DIVISION**

**IN RE: BRCA1—AND BRCA2—BASED
HEREDITARY CANCER TEST PATENT
LITIGATION**

THIS DOCUMENT RELATES TO:

UNIVERSITY OF UTAH RESEARCH
FOUNDATION, ET. AL.

v.

AMBRY GENETICS CORP.

Defendant.

**ORDER GRANTING
PLAINTIFFS' MOTION TO
DISMISS AMBRY'S ANTITRUST
COUNTERCLAIMS (DKT. 95 IN
CASE NO. 2:13-CV-00640)**

MDL Case No. 2:14-MD-02510-RJS

(Case No. 2:13-CV-00640-RJS)


Judge Robert J. Shelby

Before the court is Plaintiff Myriad Genetics Corporation's Motion to Dismiss Antitrust Counterclaims asserted by Defendant Ambry Genetics Corporation. (Dkt. 95 in Case No. 2:13-cv-00640).

For the reasons set forth in Myriad's briefing on the Motion and its argument at the hearing on June 6, 2014, which the court adopts and incorporates, the court GRANTS the Motion. The counterclaims for Antitrust Violations of the Sherman Act that Ambry has asserted against Myriad are DISMISSED without prejudice to refile.

SO ORDERED this 6th day of June, 2014.

BY THE COURT:



Judge Robert J. Shelby